Zenshine Pharma will present important research results at the AACR 2021
Date / 2021.02.23

At the 2021 annual meeting of the American Association for Cancer Research (AACR), Zenshine Pharma will presentrecent preclinical and  clinical design and studies for its internal research programs, including:

    • A phase 1/2a, dose escalation and dose-expansion study of ZX-101A in patients with relapsed/resistant or refractory advanced hematologic malignancies; 
    • A next-generation PI3Kδ/ϒ inhibitor , ZX-101A inhibiting tumor growth by enhancing anti-tumor immunity;
    • Selective PI3Kϒ inhibitor ZX-4081 reprograms the tumor microenvironment to facilitate anti-cancer immunit;
    • Potent ENPP1 inhibitors activating STING pathway in tumor microenvironment.

Link of 2021 AACR Annual Meeting:

Back to list